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The Sasakawa Memorial Health Foundation (SMHF) has just published a fascinating book:
“A Life Fighting Leprosy: a collection of the speeches and writings of Dr Yo Yuasa”, which
will be of interest to many readers of Leprosy Review, and beyond.1 Few, if any, individuals
have played so many important roles in the field of leprosy over the past several decades as
has Dr Yuasa: from clinical medical officer in leprosy hospitals in Hong Kong and Nepal, to
Secretary and then President of the International Leprosy Association, to Medical and then
Executive Director of the Sasakawa Foundation, which has been one of the largest and most
influential supporters of leprosy work around the world over the past 40 years.
The book consists of 22 speeches and essays by Dr Yuasa, delivered or written over 30
years, 1982 – 2012. Few of them have been published before, and all are elegantly written.
They cover the important period from the initiation of MDT as recommended by the WHO
Study Group in 1981, to the elimination declaration by the World Health Assembly (WHA) in
1991, to the struggles to maintain the ILA and the International Leprosy Journal in the early
2000s, and include reflections on the successive strategies developed and promoted through
ILEP, the ILA and WHO through 2012. They reveal their author to be both a pragmatist and
a philosopher.
The book contains many references to major figures in the leprosy world of recent
decades, providing glimpses of personal interactions and events behind the scenes at
important points in the history of leprosy policy. There are fascinating historical anecdotes –
such as how what became known as the first International Leprosy Congress in Berlin was
organised in 1897 because of concerns over 34 leprosy cases among Russian immigrants to
Prussia. And we learn of a bargain between Riochi Sasakawa, founder of the SMHF, and
Halfdan Mahler, Director General of WHO, in 1974/5, when WHO accepted $500,000 for
leprosy work only on the condition that an equivalent amount from the SMHF went to rescue
a funding shortfall of the Smallpox Eradication Programme.
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For many readers, the most interesting portions of the book will be those which describe
the background to and evolution of the global leprosy elimination initiative and its sequelae,
with which Dr Yuasa was intimately involved for the latter 20 years of his career. This is
touched upon in several of the essays and speeches, and documents changes in the author’s
own views concerning the nuances of the declaration’s wording and associated policy
implications. Given the continued interest in this topic in the leprosy community, and the
proliferation of elimination targets for many diseases in recent years, these reflections are
an important contribution to public health in general, reaching well beyond the leprosy
field itself.
Dr Yuasa describes how the word ‘elimination’ was adopted from a policy promoted by
the US CDC for the ‘elimination of tuberculosis in the United States’, in which elimination
was defined as reducing the ‘case rate of tuberculosis to less than one per million population
by the year 2010.’ The adoption took place in the course of discussions between Yuasa and
Dr J W Lee (subsequent Director General of WHO) and Dr R Jacobson (of Carville) in the
Western Pacific Regional Office (WPRO) in Manilla in 1989. In considering options for
leprosy control in the region, Yuasa, Lee and Jacobson decided to call the policy ‘Elimination
of leprosy as a major public health problem by the year 2000’. There is an interesting
comment (p 263) that Dr Lee was ‘reprimanded’ for this decision by Dr Noordeen, in Geneva,
for not consulting beforehand with the WHO leprosy Unit!
We also learn how Noordeen then adopted the elimination target idea from WPRO, and
proposed it to the World Health Assembly in 1991, but with an important change – the
removal of the word ‘major’ - so that the target was phrased as ‘elimination of leprosy as a
public health problem by the year 2000’, defined in a footnote thus: “Elimination of leprosy
as a public health problem is defined as the reduction of prevalence to a level below one case
per 10 000 population.” Yuasa comments with perfect irony that this was done in Geneva with
no consultation with WPRO (p 263)! This little anecdote provides a unique insight into the
genesis of the WHA declaration, and may lead us to reflect on the nature and extent of
consultation appropriate for declarations put to international bodies, which can in turn be so
influential in directing national and global policies and actions.
Equally if not more important than the issue of process is the precise wording change
between the WPRO and WHA declarations – from “elimination as a major public health
problem” to “elimination as a public health problem”. Yuasa is sensitive to this semantic
issue, and refers to it explicitly in an essay published in 2011 (p 222). This may have been
particularly problematic because of the leprosy context, insofar as it appeared to place the
WHO at odds with the responsibility of leprosy workers on the ground. Leprosy is an
infectious disease, reflecting past transmission of an infectious agent from some source, and
the possibility of further transmission to others in the community. These are public health
concerns, by definition. Beyond that, leprosy is unusual in terms of the stigma and fear it
raises in most societies, which often brings a variety of complex issues for communities with
leprosy cases. Dealing with these issues is part of the responsibility of leprosy workers at
every level, worldwide, and one can easily argue that every single leprosy case raises public
health issues, and is thus of public health importance. In this vein one may agree with the
1989 WPRO resolution’s wording, and with Dr Yuasa, that a small number of leprosy cases
may not constitute a major public health problem, given that there may well be other
problems of greater magnitude, be they HIV or polio or measles vaccine coverage : : : but to
imply that they raise no problem at all is less appropriate.
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It is interesting that Dr Yuasa discussed the wording of the WHO resolution on so many
occasions, reflecting, and in response to, the widespread concern with this issue throughout
the leprosy community. Though he described the 1991 elimination declaration as a “brilliant
marketing manoeuvre” which encouraged the mobilisation of resources and energy for
leprosy during the 1990s (p 170), several chapters document his growing concern that the
elimination word became less appropriate after the initial phase of the programme – in
particular that it logically implies the need for eradication (reduction to zero), a target which
he came to appreciate was as not feasible in practice. He explicitly comments on the
importance of the animal reservoir in some areas of the world, which makes eradication
effectively impossible (p 141). As a result of his reflections on the semantics of elimination,
and his own deep concerns over the important social implications of leprosy, even as a
symbol of human intolerance, Dr Yuasa came to favour a goal for leprosy control described at
the time of the 1998 Beijing Congress as ‘a world without leprosy’ and later as ‘a world
without leprosy-related problems, both medical and social.’ (p 242). It is interesting that a
version of the shorter, former, phrase (which was ultimately rejected by Yuasa as implying
eradication and thus effectively impossible – p 264), is included as subtitle for WHO’s
recently released “Global Leprosy Strategy 2016 – 2020: Accelerating towards a leprosy-free
world”.2 The tension between aspiration versus marketing versus politics versus feasibility of
public health ambitions and slogans is palpable throughout this book.
All this makes for fascinating reading, and is important history, documenting the
experiences, opinions and reflections of one of the most influential figures in the leprosy
world of recent times. We are grateful to Dr Yuasa for his many contributions, and to the
Sasakawa Foundation - not only for their generous support of so much leprosy work – but for
their decision to publish this revealing memoir.
II
The Yuasa memoir provides a thought-provoking background against which to contemplate
the current Global Strategy.2 The WHO document refers to the successive quinquennial
plans and notes that “They have been moving from targets on ‘elimination’ in terms of
prevalence of the disease to targets that emphasise a decrease in the number of new cases with
Grade 2 Disability (G2D) to promote early detection and reduction in transmission.” (p 2)
Specifically it outlines a vision of a “leprosy free world” (apologies to Dr Yuasa!), a goal “to
further reduce the global and local leprosy burden” and three main targets: “Zero G2D among
paediatric leprosy patients”; “Reduction of new leprosy cases with G2D to less than one case
per million population”: and “Zero countries with legislation allowing discrimination on the
basis of leprosy”.
An ambitious series of activities is proposed, including the collection of 23 performance
indicators, ranging from new case detection statistics, to the proportion of contacts screened,
to the availability of data to assess the level of stigma, to the number and proportion of drug
resistance cases. There is emphasis on six guiding principles: strengthening government
commitment, sustaining expertise, providing quality services focusing on women and
children, enhancing participation of persons affected by leprosy in leprosy services,
protection of human rights, and encouraging research. There are three pillars: to strengthen
government ownership, to stop leprosy and its complications, and to stop discrimination
and promote inclusion. Finally there are Implementation plans, set out in four categories,
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relating to: regional and country implementation, monitoring of targets and indicators
globally and at country level, advocacy, and changes to WHO technical advisory bodies. It is
a very large agenda, and while all involved in leprosy may agree with most of the proposals,
some will wonder if the programme can succeed on so many fronts. Some prioritization will
be necessary. One may ask, for example, to what extent targets need to be achievable, as well
as – or as opposed to – being aspirational. This is a major issue in public health (indeed in all
aspects of development) today as targets proliferate, with goals to “eradicate” this,
“eliminate” that, “interrupt” this, “stop” this, “end” that : : : .
We have just completed the last quinquennial plan (2011 – 2015), which proposed a
target of “reducing the rate of new cases with Grade-2 Disability per 100,000 population by at
least 35% by the end of 2015 compared to the baseline at the end of 2010”.3 Unfortunately,
not only was this target not met, but the detection rate of G2D hardly changed at all.2,4 Should
one ask why the target was missed? Should one ask how the target came to be set in the first
place? If it was an error, or a miscalculation, should such mistakes be avoided in the future?
Does it matter? What are targets for?
In considering targets, it is interesting to reflect that Dr Yuasa became concerned that
some of the targets which had been proposed were not achievable, once the armadillo
reservoir of M. leprae had been recognised. This fact is not mentioned at all in the Global
Strategy, despite its elegant confirmation through genetic sequencing of bacilli from human
and armadillo sources in recent years,5 and the recognition that this reservoir is now
increasing in geographic extent in at least one country, the USA, along with associated human
cases.6 The reservoir species is found throughout most of Latin America – but there is as
yet no solid evidence of its role in human leprosy south of the Rio Grande River. This is now
an important research question.
The latest numerical targets (Zero G2D among paediatric leprosy patients, and Reduction
of new leprosy cases with G2D to less than one case per million population) might in theory
be achievable, even if M. leprae infection is to persist, if it could be ensured that incidence of
infection in humans is low and cases are recognised early, and managed properly. Assurance
of these conditions in practice will not be easy, however, given the difficulty of diagnosing
early leprosy and the state of many leprosy control services, which have been wound down as
a result of WHO’s declaration that leprosy was no longer a public health problem and the
misinterpretation by some that leprosy had in effect been eradicated.4,7,8 We may recall
Dr Yuasa’s concern over words and their implications.
Several authors have argued for the introduction of more systematic contact tracing and
chemoprophylaxis, which would probably reduce new infections and incidence, and this is
referred to in the new Strategy document, with the proviso that practicability in the field
still needs to be shown.2,4 If this can be organised and funded, so much the better, as it
might accelerate leprosy’s decline to some degree. However, the relative contributions of
improved living standards, widespread BCG vaccination of infants (not mentioned in the
Strategy) and case detection and treatment, let alone chemoprophylaxis of contacts, to
declines in leprosy incidence, are likely to differ between populations, and have nowhere
been rigorously defined.
It has been noted that new case detection numbers at the global level have remained
relatively constant in recent years.4 In fact, they have varied considerably within and between
countries, but the global total has declined every year but one (it increased from 226,626 to
232,857 between 2011 and 2012).9 One might argue, however, that the problem is not that the
numbers of new cases appear to be declining slowly in recent years, as a slow decline is at
Perspective on the history of leprosy 149
least a decline, and a rapid decline is unlikely for a condition with a long incubation period,
let alone no test for infection and generally poor control services. The larger problem is that
many of the published numbers are of questionable validity.10
Surveillance is an essential aspect of public health, and this poses a major problem in the
leprosy field. It is therefore commendable that the new strategy does mention a commitment
for “strengthening surveillance and health information systems for programme monitoring”
and states that “A pool of monitors shall be trained.” This is crucial, as the programme
ultimately turns to the numbers reported in order to monitor progress. However, nineteen
(40% of) African nations are recorded as ‘NR’ (no report) in the most recent summary.9
Europe does not report at all. Some Latin American countries report zero new or prevalent
cases after reporting more than a hundred a very few years ago. And the India data
(specifically the 66% decline in numbers of cases detected, from 474,286 to 161,457 between
2000 and 2005) have repeatedly been questioned : : : , all leading to the claim that millions of
cases may have failed to be reported in recent years.11 At the end of the day, the numbers are
what matters, and if they are not robust, and not credible, the entire programme suffers.
Programmes with serious surveillance typically include a condition that the comparison of
numbers to targets must be based upon high quality surveillance - and they set out hard criteria
for such quality (the polio programme is the most prominent example of this today).12,13 We
encourage that this aspect of the leprosy strategy, to improve and monitor surveillance in all
endemic countries, receives high priority and critical attention, in the years to come.
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